Results 151 to 160 of about 19,188,680 (306)

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source

FOLFIRI as second-line treatment of metastatic biliary tract cancer patients

Autopsy and Case Reports, 2019
The combination of cisplatin and gemcitabine is the standard first-line treatment of metastatic biliary tract cancer (BTC) patients. The benefit of second-line chemotherapy in these patients is controversial.
Rafael Caparica, Adrien Lengelé, Winnie Bekolo, Alain Hendlisz   +3 more
doaj  

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

Molecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir, Elena Haro‐Martínez, Sandra Blasco‐Benito, Chiara Cannatà, José Ángel Palomeque, Anna López‐Plana, Maria Sanz‐Flores, Marc Sabartés, Cristina Fornaguera, Toni Celià‐Terrassa   +9 more
wiley   +1 more source

Engineering IL‐4 resistant proinflammatory human myeloid cells for cancer immunotherapy

Molecular Oncology, EarlyView.
We developed a scalable workflow to generate proinflammatory human myeloid cells. CRISPR/Cas9‐edited CD34+ hematopoietic stem and progenitor cells were expanded and differentiated with M‐CSF. Deletion of STAT6 or STAT6/NFKB1 enhanced macrophage proinflammatory gene expression and cytokine secretion in the presence of IL‐4 while maintaining antibody ...
Theresa Barberi, Alan D. Friedman
wiley   +1 more source

Second-line medications for women aged 10 to 50 years with idiopathic generalized epilepsy

Importance: Women with idiopathic generalized epilepsy (IGE) face challenges in treatment due to limited options that are both effective and safe.Objective: To evaluate the effectiveness and safety of substitution monotherapy vs add-on therapy as second ...
Emanuele Cerulli Irelli (8639760), Carlo Di Bonaventura (8639766), Javier Peña-Ceballos (14815933), Norman Delanty (7895990), Women with Epilepsy Treatment Options and Research (WETOR) study group (20964914), Patrick B Moloney (17107451)   +5 more
core  

The multifaceted roles of lysosomes in cancer

Molecular Oncology, EarlyView.
Lysosomes support cancer cell adaptation by integrating macromolecule degradation and nutrient recycling with nutrient sensing, inter‐organelle communication and immune regulation. These interconnected functions can promote tumour growth, stress tolerance and therapy resistance, while also creating context‐dependent vulnerabilities that may be ...
Jia Li, Kevin M. Ryan
wiley   +1 more source

Attitudes of cancer patients toward ctDNA‐based liquid biopsy for follow‐up

Molecular Oncology, EarlyView.
This mixed‐methods study explored cancer patients' experiences, knowledge, and preferences regarding ctDNA‐based liquid biopsy for follow‐up. Awareness of ctDNA was low and recall of previous liquid biopsy was imperfect, yet acceptance was high.
Siddharth Chhajlani, Laura Mariën, Caro De Weerdt, Sanne Wouters, Laure‐Anne Teuwen, Hans Prenen, Katleen Janssens, Timon Vandamme   +7 more
wiley   +1 more source

Second-line treatment selection for advanced hepatocellular carcinoma: a network meta-analysis with reconstructed survival curves and integrated benefit-risk assessment. [PDF]

Front Immunol
Li X, Nie G, Wang Y, Xu J, Yang J, He E, Liu G, Li B, Lu J.   +8 more
europepmc   +1 more source

The impact of leukocyte‐associated RNA retention on platelet RNA‐based cancer detection

Molecular Oncology, EarlyView.
Platelets carry RNA signals that may help detect cancer, but platelet samples can also retain RNA from white blood cells. We found that this retained white blood cell signal did not significantly affect machine learning cancer classification, suggesting that the cancer‐related RNA signal in platelets is largely independent of leukocyte‐associated RNA ...
Michał Sieczczyński, Krzysztof Pastuszak, Anna Samelak‐Czajka, Zuzanna Cemka, Paulina Jackowiak, Tomasz Stefaniak, Sylwia Łapińska‐Szumczyk, Jacek Jassem, Anna J. Żaczek, Matthew T. Rondina, Myron G. Best, Sjors G. J. G. In 't Veld, Anna Supernat   +12 more
wiley   +1 more source